Technology ID

Clinical Outcome Predictors for Mantle Cell Lymphoma

Lead Inventor
Staudt, Louis (NCI)
Scott, David (British Columbia Cancer Agency)
Wright, George (NCI)
Rosenwald, Andreas (University Of Wurzburg)
Abrisqueta, Pau (British Columbia Cancer Agency)
Braziel, Rita (Oregon Health and Science University (OHSU))
Guerri, Elias (University of Barcelona)
Chan, Wing (City of Hope Medical Center)
Connors, Joseph (British Columbia Cancer Agency)
Villa, Diego (British Columbia Cancer Agency)
Fu, Kai (University of Nebraska Medical Center)
Gascoyne, Randy (British Columbia Cancer Agency)
Greiner, Timothy (University of Nebraska Medical Center)
Jaffe, Elaine (NCI)
Slack, Graham (British Columbia Cancer Agency)
Cook, James (Cleveland Clinic)
Delabie, Jan (University Health Network, University of Toronto)
Ott, German (Robert Bosch Stiftung)
Rimsza, Lisa (Mayo Clinic Arizona)
Weisenburger, Dennis (City of Hope Medical Center)
Mottok, Anja (British Columbia Cancer Agency)
Jares, Pedro (Hospital Clinic de Barcelona)
Therapeutic Areas
Development Stages
Clinical Phase I
Lead IC

Mantle cell lymphoma (MCL) is a group of aggressive B-cell lymphomas displaying heterogeneous outcomes after treatment.  Some patients have the slowly progressing disease that does not require immediate treatment, while others have a disease that rapidly progresses despite highly aggressive treatment. A number of prognostic tools have been described to determine whether patients have slow or rapidly progressing diseases, including the mantle cell lymphoma International Prognostic Index (MIPI) and biomarkers, such as KI-67.

Researchers have discovered a novel method of predicting a MCL patient’s overall survival prognosis (poor, intermediate, or good) by measuring the gene expression profile of a specific subset of biomarkers from a biopsy and using a set of statistical algorithms to analyze the results and produce a “survival score”.  The survival score enables a physician to determine the best course of treatment, such as a less aggressive or more aggressive treatment protocol or an experimental treatment that would be the most beneficial for an MCL patient.

Competitive Advantages:

  • Does not require fresh frozen samples, utilizes formalin-fixed paraffin-embedded (FFPE) samples
  • In contrast to current KI-67 assay, the subject technology is reproducible

Commercial Applications:

  • Mantle cell lymphoma prognostic tool
Licensing Contact:
Bhattacharya, Ramona